People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lb Pharmaceuticals Inc | — | Pharmaceuticals | Series D+ | $141.4M | $1.5B | 2023 |
Anna Eramo at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Anna Eramo on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Ruffolo | 1 | 8 |
| Chen Yu | 1 | 7 |
| Rebecca Luse | 1 | 3 |
| Rajul Jain | 1 | 3 |
| Ran Nussbaum | 1 | 3 |
| Marc Panoff | 1 | 2 |
| Piero Poli | 1 | 1 |
| Mark Panoff | 1 | 1 |
| Lauren Stipp | 1 | 1 |
| Zachary Prensky | 1 | 1 |
| Andrew Vaino | 1 | 1 |
| Simon Basseyn | 1 | 1 |
| Edmund Sullivan | 1 | 1 |
| Vincent Grattan | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.